Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Integrated Diagnostics Holdings's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 0.00.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Integrated Diagnostics Holdings's liquidation value for the
three
months ended in Mar. 2026 was $0.00 Mil.
Integrated Diagnostics Holdings (LSE:IDHC) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Integrated Diagnostics Holdings's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:
2. In Ben Graham's calculation of liquidation value, Integrated Diagnostics Holdings's accounts receivable are only considered to be worth 75% of book value:
Integrated Diagnostics Holdings's liquidation value for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Diagnostics Holdings Change In Receivables Related Terms
Integrated Diagnostics Holdings Change In Receivables Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Diagnostics Holdings Change In Receivables Chart
Integrated Diagnostics Holdings Change In Receivables Calculation
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of $0.00 Mil mean?
Integrated Diagnostics Holdings (LSE:IDHC) has a Change In Receivables of $0.00 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Integrated Diagnostics Holdings and its competitors.
Is Integrated Diagnostics Holdings' Change In Receivables too high?
Integrated Diagnostics Holdings' current Change In Receivables is $0.00 Mil. Overall, Integrated Diagnostics Holdings has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' Change In Receivables compare to TMO and DHR?
Integrated Diagnostics Holdings' Change In Receivables of $0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Diagnostics & Research company?
A good Change In Receivables depends on the Medical Diagnostics & Research industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Integrated Diagnostics Holdings and its competitors. Integrated Diagnostics Holdings's current Change In Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.60, compared to a current price of $0.52 — trading 13.3% below its estimated fair value. The current Change In Receivables is $0.00 Mil. Integrated Diagnostics Holdings' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current Change In Receivables is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued.
The current stock price of $0.52 is trading 13.3% below its estimated GF Value™ of $0.60.
GuruFocus considers Integrated Diagnostics Holdings to be Modestly Undervalued.
Key valuation signals for LSE:IDHC:
Change In Receivables: $0.00 Mil
GF Value™: $0.60 vs. price of $0.52 (13.3% below fair value)
No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
58GF Score
Get the complete analysis for LSE:IDHC
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IDHC has been successfully added to your 
